Abuse Potential of Pregabalin
- 1.4k Downloads
Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known.
The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin.
We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin.
We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers.
Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.
KeywordsGabapentin Pregabalin Conditioned Place Preference Withdrawal Symptom Abuse Potential
Compliance with Ethical Standards
No sources of funding were used to assist with the preparation for this paper.
Conflict of interest
Ole Schjerning has received speaker honoraria from Lundbeck. Jimmi Nielsen has received research grants from Lundbeck, Pfizer and speakers honoraria from Hemocue, Lundbeck and Bristol Myers Squibb. Anton Pottegård, Mary Rosenzweig and Per Damkier state no conflicts of interest.
- 3.Medstat.dk-National Institute for Health Data and Disease Control. Usage data on Lyrica. 2014. http://medstat.dk/en. Accessed 29 Nov 2014.
- 4.Pharma Marketing. Top 50 pharmaceutical products by global sales. 2015. http://www.pmlive.com/top_pharma_list/Top_50_pharmaceutical_products_by_global_sales. Accessed 28 Oct 2015.
- 12.European Medicine Agency. Summary of product characteristics for pregabalin. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003880/WC500166172.pdf. Accessed 29 Nov 2014.
- 13.Expert P. Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend. 2003;70(3 Suppl.):S107–14.Google Scholar
- 17.Center for Drug Evaluation and Research US. Consult on abuse potential for NDA review, Lyrica (Pregabalin). In: FaDAP, editor. Review. USA: US Food and Drug Administration; 2004.Google Scholar
- 69.European Medicine Agency (EMA). Scientific discussion—Lyrica. In: Agency EM, editor. European Medicines Agency. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000546/WC500046605.pdf. Accessed 28 Nov 2015.
- 70.Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30:2069–83.PubMedCrossRefGoogle Scholar
- 74.Sugandiran NBJ. Pregabalin may cause dependence even if it is not abused. Arc Cas Rep CMed. 2014;1:1.Google Scholar